IBL HealthCare Limited has disseminated a revised presentation from its Corporate Briefing Session held on November 02, 2026, reflecting last-minute updates to key financial and strategic insights.
- The revised presentation is now available on the company's website: [IBL HealthCare Investor Relations](https://www.iblhc.com/investor-relations).
- FY2026 net revenue reached PKR 4,607.1M, a 7% increase from FY2025.
- Gross profit for FY2026 was PKR 1,644.8M, with a gross margin of 35.7%, up from 33.5% in FY2025.
- Profit before tax stood at PKR 401.3M, while profit after tax was PKR 220.4M, both reflecting a 6% increase year-on-year.
- The company has strategically refocused on two core verticals: Nutrition and Medical & Surgical Disposables, discontinuing non-aligned portfolios.
- Marketing and distribution expenses rose by 17% to PKR 1,006M, aimed at enhancing brand presence and market development in the Nutrition segment.
- The outlook for FY2027 includes deepening focus on the two verticals, new product launches, and leveraging partnerships for sustainable growth.
- Risks identified include FX exposure, import costs, and regulatory challenges, with a commitment to strong governance and risk management practices.